Journal Article

Efavirenz to Nevirapine Switch in HIV-1–Infected Patients with Dyslipidemia: A Randomized, Controlled Study

Jean-Jacques Parienti, Véronique Massari, David Rey, Patrice Poubeau and Renaud Verdon

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 45, issue 2, pages 263-266
Published in print July 2007 | ISSN: 1058-4838
Published online July 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/518973
Efavirenz to Nevirapine Switch in HIV-1–Infected Patients with Dyslipidemia: A Randomized, Controlled Study

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P < .04). A switch to nevirapine was associated with no severe adverse events.

Journal Article.  2489 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.